Stocks · News reference
Galmed Pharma Announces Continued Advancement Of Aramchol As Potential Disease-Modifying Therapy For Parkinson's Disease, Reporting Significant Progress In Development Of New Aramchol ODF Formulation
Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration.In order to improve patient convenience and long-term treatment adherence by
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 28, 2026, 11:09 AM
- Checked
- Jul 28, 2026, 11:09 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Read original at benzingaGalmed Pharma’s Subsidiary Colospan Completes Feasibility Study Supporting Development Of Intraoperative Colon Tissue Quality Assessment Platform
The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of
Read original at benzingaTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Read original at benzinga